+612 9045 4394
 
CHECKOUT
Topical Steroids in Gastroenterology and Hepatology : Falk Symposium - A. Dignass

Topical Steroids in Gastroenterology and Hepatology

Falk Symposium

By: A. Dignass (Editor), V. Gross (Editor), H. J. Buhr (Editor), O. F. W. James (Editor)

Hardcover

Published: 29th February 2004
Ships: 7 to 10 business days
7 to 10 business days
RRP $743.99
$515.25
31%
OFF
or 4 easy payments of $128.81 with Learn more
if ordered within

The topical glucocorticoid budesonide has long been well known in the medical community because of its beneficial effects in the treatment of chronic obstructive pulmonary diseases. Budesonide is characterized by a high first-pass effect and a rapid metabolism in the liver resulting in low systemic bioavailability and reduced frequency of side-effects compared to conventional glucocorticoids. For about a decade, budesonide has been used by gastroenterologists, and it has been proven especially effective in the treatment of distal ulcerative colitis and ileocolonic Crohn's disease in a number of randomized controlled clinical studies. In recent years, budesonide has also been successfully used in the management of other diseases in the field of gastroenterology, hepatology, surgery and oncology. This book, the proceedings of a Falk Workshop on 'Topical Steroids in Gastroenterology and Hepatology', held in Berlin, Germany, on 14 June 2003, critically discusses the current role of budesonide in gastroenterology, hepatology, surgery and oncology and focuses especially on potential new indications for the use of budesonide. A number of smaller clinical studies and anecdotal case reports with impressive clinical effects are reported in patients with gastrointestinal, hepatic, oncological and surgical problems. In addition, the use of budesonide for the treatment of distal ulcerative colitis and ileocolonic Crohn's disease is evaluated with respect to its role in an evidence-based management of IBD. Finally, as clinical experience with the use of budesonide is increasing, safety issues and the side-effect profile of budesonide is addressed.

Mode of action and pharmacokineticsp. 3
Safety profile and potential side-effects of budesonidep. 12
Budesonide in Crohn's diseasep. 20
Pharmacokinetics after single and multiple oral dosing of budesonide pH-modified-release capsules in patients with distal ulcerative colitisp. 30
Potential use of budesonide in inflammatory bowel diseases : extended ulcerative colitisp. 39
The role of budesonide in the treatment of collagenous and lymphocytic colitisp. 47
Budesonide in refractory spruep. 57
Potential use of budesonide in food hypersensitivityp. 63
Use of oral budesonide in paediatric inflammatory bowel diseasep. 71
The therapeutic potential of budesonide for oral mucosal diseasesp. 74
Potential use of budesonide after surgical interventions and in patients with oncological complications - functional improvement in patients with ileostomyp. 85
Budesonide treatment in pouchitisp. 97
Chemotherapy-associated diarrhoeap. 101
Acute intestinal graft-versus-host disease and budesonidep. 102
Primary biliary cirrhosisp. 115
Table of Contents provided by Blackwell. All Rights Reserved.

ISBN: 9780792387893
ISBN-10: 0792387899
Series: Falk Symposium
Audience: Professional
Format: Hardcover
Language: English
Number Of Pages: 136
Published: 29th February 2004
Publisher: Springer
Country of Publication: NL
Dimensions (cm): 23.5 x 15.5  x 1.27
Weight (kg): 0.86